Lifevantage vs Mannatech
LFVN and MTEX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFVN and MTEX compare
Lifevantage is the larger company, worth 5.1 times as much as Mannatech ($62.3M against $12.2M).
Mannatech grew revenue faster over the last twelve months (−6.6% versus −24.8% for Lifevantage).
Lifevantage keeps more of each dollar of sales as profit, with a net margin of 1.6% compared with −0.41% at Mannatech.
Lifevantage pays a dividend yielding 3.8%; Mannatech does not pay one.
Lifevantage scores higher on the StockData Score (16 against 9 for Mannatech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFVN | MTEX |
|---|---|---|
| Size and price | ||
| Market cap | $62.3M | $12.2M |
| Share price | $4.97 | $6.30 |
| Change, 1 year | −25.2% | −33.8% |
| Change, 5 years | −32.7% | −83.5% |
| Beta (5Y) | 0.38 | 0.36 |
| Employees | 223 | 387 |
| StockData Score | ||
| Total score | 16 (better) | 9 |
| Valuation score | 4 (better) | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 | 4 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 23.7× | – |
| P/S | 0.4× | 0.1× (better) |
| P/B | 1.9× (better) | 2.3× |
| EV/EBITDA | 7.4× | 4.8× (better) |
| P/FCF | 7.2× | – |
| PEG | 0.91 | – |
| FCF yield | 14.0% (better) | −5.3% |
| Fair value | $6.48 | $11.41 |
| Margin of safety | 23.3% | 44.8% (better) |
| Growth | ||
| Revenue growth (TTM) | −24.8% | −6.6% (better) |
| Revenue growth, 5Y average | −3.7% (better) | −6.5% |
| Net income growth (TTM) | −73.1% | – |
| EPS growth (TTM) | −72.7% | – |
| EPS growth, 5Y average | −15.0% | – |
| Profitability | ||
| Gross margin | 76.5% (better) | 75.7% |
| Operating margin | 2.1% (better) | 0.91% |
| Net margin | 1.6% (better) | −0.41% |
| FCF margin | 5.1% (better) | −0.63% |
| Return on equity | 8.2% (better) | −7.0% |
| Return on invested capital | 14.0% | 17.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.53 (better) |
| Net debt / EBITDA | – | −1.36 |
| Interest coverage | – | 2.0× |
| Current ratio | 1.91 (better) | 1.18 |
| Altman Z-score | 2.42 | 4.10 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 3.8% | – |
| Payout ratio | 88.2% | – |
| Years of dividend growth | 1 | – |
| Buyback yield | 2.4% | – |
| Shareholder yield | 6.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 47.2% | 7.9% |
| Held by insiders | 27.8% | – |
| Insider net buying, 12 months | $54.8K | $62.2K (better) |
| Short interest, % of float | 10.0% | – |
Go deeper
- LFVN stock overview
- LFVN income statement
- LFVN valuation and score
- MTEX stock overview
- MTEX income statement
- MTEX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.